Healthcare giant Grifols accused of manipulating finances by short seller Gotham City, stock plummets 

Plas­ma-de­rived med­i­cines man­u­fac­tur­ing com­pa­ny Gri­fols has been ac­cused of ma­nip­u­lat­ing its re­port­ed debt and EBIT­DA by UK-based hedge fund Gotham City Re­search, caus­ing its stock $GRFS to plum­met by about 20% on Tues­day af­ter­noon.

The Span­ish health­care gi­ant said Gotham City’s al­le­ga­tions were “false in­for­ma­tion and spec­u­la­tions” in an SEC fil­ing on Tues­day.

“As a com­pa­ny com­mit­ted to trans­paren­cy, in­tegri­ty, and eth­i­cal con­duct, we cat­e­gor­i­cal­ly de­ny and re­ject any al­le­ga­tions of wrong­ful ac­count­ing or re­port­ing prac­tices of our con­sol­i­dat­ed fi­nan­cial state­ments,” Gri­fols said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.